Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease

被引:0
|
作者
Iskandarovna, Khodzhanova Shakhnoza [1 ]
机构
[1] Tashkent Med Acad, Dept Fac & Hosp Therapy Nephrol & Hemodialys 2, Tashkent, Uzbekistan
关键词
acetylsalicylic acid; coronary heart disease; spontaneous platelet aggregation; ADP-induced platelet aggregation; aspirin resistance;
D O I
10.47750/pnr.2022.13.S09.086
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To study the aggregation activity of platelets in patients with ischemic heart disease depending on the long-term intake of acetylsalicylic acid (ASA). Material and methods. The study included: 116 patients with coronary artery disease with stable angina pectoris, taking a standard dose of aspirin 75 mg/day. during various terms. Patients with SSN were divided into 4 groups according to the duration of taking ASA. Platelet aggregation was measured using a laser platelet aggregation analyzer Alat-2 Biol, with computer processing according to the AGGR program. Adenosine diphosphate (ADP) in concentrations of 0.1, 1.0, 5.0 mmol/l was used as an inductor. The results of the study of patients taking ASA for more than 5 years showed that spontaneous aggregation and ADP-induced platelet aggregation were higher than in patients taking the drug for less than 5 years. Statistically significant differences were observed when compared with a group of patients taking ASA for less than a year (spontaneous aggregation of 1.7 +/- 0.09 (p<0.05), 0.1 mu m ADP-induced aggregation of 6.58 +/- 0.86 (p<0.05), 1.0 mu m ADP-induced aggregation of 16.51 +/- 1.63 (p<0.01), 5.0 mu m ADP-induced aggregation 58.44 +/- 3.72 (p<0.01). Conclusion. Thus, the results showed that with an increase in the duration of aspirin intake, there was a change in both spontaneous and ADP-induced platelet aggregation with a statistically significant increase.
引用
收藏
页码:754 / 760
页数:7
相关论文
共 50 条
  • [21] Smoking and lipoprotein abnormalities on platelet aggregation in coronary heart disease
    Mansur, AD
    Caramelli, B
    Vianna, CB
    Chamone, D
    Ramires, JAF
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 1997, 62 (02) : 151 - 154
  • [22] Platelet aggregation is dependent on platelet count in patients with coronary artery disease
    Wurtz, Morten
    Hvas, Anne-Mette
    Kristensen, Steen Dalby
    Grove, Erik Lerkevang
    THROMBOSIS RESEARCH, 2012, 129 (01) : 56 - 61
  • [23] Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy
    Camargo, L. M.
    Franca, C. N.
    Izar, M. C.
    Bianco, H. T.
    Lins, L. S.
    Barbosa, S. P.
    Pinheiro, L. F.
    Fonseca, F. A. H.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2014, 47 (05) : 432 - 437
  • [24] EFFECTS OF LIPIDS ON PLATELET-AGGREGATION IN BLOOD FROM PATIENTS WITH CORONARY HEART-DISEASE
    BORNIKOV, VT
    ZAINUTDINOV, BR
    ISHANKHODZHAYEV, TM
    SAATOV, TS
    AKMALOV, DM
    KARDIOLOGIYA, 1989, 29 (06) : 22 - 24
  • [25] Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization
    Gao, Peixian
    Xiong, Hui
    Zheng, Zhe
    Li, Lihuan
    Gao, Runlin
    Hu, Sheng-Shou
    PLATELETS, 2010, 21 (03) : 183 - 190
  • [26] EFFECT OF TIMOLOL ON PLATELET-AGGREGATION IN CORONARY HEART-DISEASE
    THAULOW, E
    KJEKSHUS, J
    ERIKSSEN, J
    ACTA MEDICA SCANDINAVICA, 1981, : 101 - 109
  • [27] PLATELET-AGGREGATION IN 93 CASES OF CORONARY HEART-DISEASE
    YU, GR
    LIANG, GR
    HUANG, MX
    ZHENG, DS
    HUANG, DJ
    ZHONG, DS
    XIE, XL
    YAO, GD
    ZHANG, JL
    DING, CY
    GUO, JH
    CHINESE MEDICAL JOURNAL, 1985, 98 (11) : 847 - 850
  • [28] Relationship between levels of fibronectin and of platelet aggregation in coronary heart disease
    Domaniç, N
    Ulutin, T
    Sönmez, H
    Öztürk, Z
    Bayram, Ç
    Turgut, M
    Öztekin, GE
    Kökoglu, E
    ATHEROSCLEROSIS, 1999, 146 : S39 - S39
  • [29] Antiplatelet drugs do not protect from platelet-leukocyte aggregation in coronary artery disease
    Schulte, Christian
    Pieper, Luise
    Frye, Maike
    Waldeyer, Christoph
    Neumann, Johannes T.
    Brunner, Fabian J.
    Pula, Giordano
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (02) : 553 - 557
  • [30] Antiplatelet treatment for coronary heart disease
    Clappers, N.
    Brouwer, M. A.
    Verheugt, F. W. A.
    HEART, 2007, 93 (02) : 258 - 265